Innovative Target Modulators for FAP-targeting UniCAR T therapy
Organisation: Helmholtz Zentrum Dresden Rossendorf (HZDR), Germany
Supervisors: Prof. Dr. Michael Bachmann, Dr. Anja Feldmann, and Dr Claudia Arndt
Hi, my name is Hugo Boutier and I am from France. In summer 2022, I graduated with a Master’s degree in biotechnology at the Bordeaux Graduate School of Biomolecule Technologies (ENSTBB). For my last year at the ENSTBB, I decided to join the University College of London (UCL) to study immunology and cancer biology. Throughout my course, I have developed a great interest in health research, especially in the field of immuno-oncology. I am now proud to be a PhD student in the OncoProTools consortium, which aims to develop new strategies for both cancer diagnosis and therapy.
As doctoral candidate 4, my aim is to develop novel combinatorial strategies for the diagnosis and treatment of solid tumors using both immunotherapy and endoradiotherapy. My project is based on the use of a modular Chimeric Antigen Receptor (CAR) T cell technology, known as the UniCAR system, and focuses particularly on targeting the solid tumors that overexpress the Fibroblast Activation Protein (FAP). My research will mainly be conducted at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) in Dresden (Germany), with additional secondments at the University of Copenhagen (UCPH, Denmark) and Cromed (Budapest, Hungary).
